Epic Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Founded: 2008HQ: Laurelton, United States

Overview

Epic Pharma is a private, commercial-stage generic drug manufacturer established in 2008 with a mission to improve medicine accessibility and affordability. The company leverages its FDA and DEA-approved facility in New York to produce a diverse portfolio of generic medications across therapeutic areas including cardiovascular, CNS, anti-infectives, and controlled substances (CII-CV). Its business model combines internal product development and sales with contract manufacturing services, emphasizing quality, regulatory compliance, and a reliable supply chain. Epic Pharma is a revenue-generating entity positioned in the competitive but essential generic pharmaceuticals market.

CardiovascularCentral Nervous System (CNS)Anti-infectivesRespiratory

Technology Platform

cGMP manufacturing facility specializing in oral solid dosage (tablets, capsules, powders) with expertise in Sustained/Controlled Release formulations. Capabilities extended via collaboration to injectables, ophthalmics, nasal sprays, and softgels. Integrated digital compliance (EDI, DSCSA) for traceability. DEA-approved for controlled substances (CII-CV).

Funding History

1

UndisclosedUndisclosedUndisclosedJun 15, 2016

FDA Approved Drugs

1

CLINDAMYCIN HYDROCHLORIDEANDAMar 22, 2004

Opportunities

The growing demand for affordable medicines due to healthcare cost pressures and patent expirations creates a steady market.

Capabilities in complex generics (controlled release) and controlled substances offer access to less competitive, higher-margin niches.

The contract manufacturing (CDMO) business provides a diversified revenue stream leveraging its FDA-approved U.S.

facility.

Risk Factors

Severe price erosion and intense competition in the generic drug market pressure profitability.

Significant regulatory risk from FDA/DEA compliance requirements; any failure could halt operations.

Dependence on global supply chains for APIs creates vulnerability to shortages and cost fluctuations.

Competitive Landscape

Epic Pharma competes in the highly fragmented generic pharmaceuticals market against large global players (e.g., Teva, Sandoz, Mylan/Viatris) and numerous agile Indian manufacturers. Its differentiation is based on U.S.-based manufacturing, quality compliance, expertise in controlled substances and complex formulations, and a dual product/CDMO model.